All In Biotech

Drug Trial Radar · NCT07200830

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,524 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,524

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Sep 9, 2034

Study completion Sep 9, 2034

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Oct 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study is for patients with hormone resistant prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Hormone resistant prostate cancer often has many cells containing a protein called prostate-specific membrane antigen (PSMA) on their surface. The normal cells in the prostate do not normally express as much PSMA protein on their surface as cancer cells. Lutetium 177 Lu PSMA RLT binds to the PSMA protein on the tumor cells. It builds up in these cells and gives off radiation that may kill them. Typically, this medication is given at the same dose every 6 weeks for up to 6 doses. In this trial, researchers want to see if treatment following the first two doses of lutetium 177 Lu PSMA RLT can be delayed until there is evidence of disease activity. This may be an effective way to improve quality of life without decreasing lifespan in patients with advanced prostate cancer.

Conditions

  • Metastatic Castration-Resistant Prostate Carcinoma
  • Metastatic Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Lutetium Lu 177 Vipivotide TetraxetanDrug

    Given IV

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Patient MonitoringProcedure

    Undergo PSA monitoring

  • Computed TomographyProcedure

    Undergo CT

  • Bone ScanProcedure

    Undergo Bone Scan

  • PSMA PET ScanProcedure

    Undergo PSMA PET Scan

  • MRIProcedure

    Undergo MRI

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to 5 years
  2. Quality of lifeTime frame: Up to 30 months

Locations

142 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UC San Diego Medical Center - Hillcrest

    San Diego, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado · Recruiting

  • Memorial Hospital North

    Colorado Springs, Colorado · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • CTCA at Southeastern Regional Medical Center

    Newnan, Georgia · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois · Recruiting

  • Decatur Memorial Hospital

    Decatur, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • SSM Health Good Samaritan

    Mount Vernon, Illinois · Recruiting

  • Cancer Care Center of O'Fallon

    O'Fallon, Illinois · Recruiting

  • HSHS Saint Elizabeth's Hospital

    O'Fallon, Illinois · Recruiting

  • Northwestern Medicine Oak Brook

    Oak Brook, Illinois · Recruiting

  • Northwestern Medicine Orland Park

    Orland Park, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois · Recruiting

  • Midwestern Regional Medical Center

    Zion, Illinois · Recruiting

  • Mary Greeley Medical Center

    Ames, Iowa · Recruiting

  • McFarland Clinic - Ames

    Ames, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa · Suspended

  • McFarland Clinic - Boone

    Boone, Iowa · Suspended

  • Saint Anthony Regional Hospital

    Carroll, Iowa · Suspended

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa · Suspended

  • Iowa Methodist Medical Center

    Des Moines, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Des Moines Clinic

    Des Moines, Iowa · Suspended

  • Broadlawns Medical Center

    Des Moines, Iowa · Suspended

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    Des Moines, Iowa · Suspended

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.